PURPOSE
This protocol specifies the criteria and procedures for pharmacists to initiate the dispensing and administration of naltrexone for medication assisted treatment to individuals for opioid use disorder recovery.

PHARMACIST EDUCATION AND TRAINING
Prior to initiating the dispensing and administration of naltrexone under this protocol, pharmacist(s) must have received education and training in opioid use disorders and naltrexone therapy, including review of American Society of Addiction Medicine’s National Practice Guideline for the use of medications in the treatment of addiction involving opioid use\(^1\), from a provider accredited by the Accreditation Council for Pharmacy Education, or by a comparable provider approved by the Kentucky Board of Pharmacy.

Provider of Training: _________________________________

Date Training Completed: _________________________________

CRITERIA
Pharmacist(s) authorized to initiate the dispensing and administration of naltrexone will follow the most current American Society of Addiction Medicine, The National Practice Guideline for the use of medications in the treatment of addiction involving opioid use\(^1\).

Inclusion criteria:
Any individual, 18 years or older, who has been diagnosed with an opioid use disorder and has met the following criteria:

- Had a baseline medical screening exam, including evaluation of hepatic function within the past 14 days
- Is adequately detoxified from opioids as verified by point-of-care urine drug screen
- Has no signs or symptoms of withdrawal as verified by Clinical Opiate Withdrawal Scale (COWS) \(^1\)
- Is able to provide informed consent to receive treatment

Exclusion criteria:
- Individuals who are pregnant are not eligible to receive therapies under this protocol and should be referred to their primary care or Ob/Gyn provider.

\(^1\) Available at: https://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf
• Individuals who have contraindications (severe allergic reaction to naltrexone or any component of the extended-release injectable naltrexone formulation).
• Individuals with acute hepatitis or liver failure or liver function tests >3 times the upper limits of normal (ULN).
• Individuals testing positive for opioids via a point-of-care urine drug screen

MEDICATIONS
This protocol authorizes pharmacists to initiate the dispensing and administration of the following medications as referenced in the manufacturer’s product information.2

1) Extended-release injectable naltrexone (Vivitrol®)
2) Oral naltrexone (ReVia®, Depade®), which is used solely for the initial withdrawal challenge

PROCEDURES FOR INITIATION OF THERAPY
Naltrexone will be initiated only in carefully selected individuals based on relevant medical and social history and consideration of contraindications and precautions of therapy as outlined in the pharmacologic product guide and identified through assessment and screening.2

Relevant Medical and Social History
• Past medical history, including an active diagnosis of opioid dependence disorder
• Current medications
• Allergies and hypersensitivities
• Previous medication assisted therapy attempts and failures
• Psychosocial counseling treatment plans

Contraindications and Precautions
• Hypersensitivity to naltrexone, or components of the naltrexone diluent
• Pregnancy
• Chronic opioid analgesics for chronic pain syndromes
• Current opioid dependence, including partial agonists
• Acute hepatitis or liver failure or liver function tests >3x ULN
• Positive urine drug screen for opioids
• Positive opioid withdrawal assessment- indicated by COWS score 5 or greater
  o Injection will not be provided to individuals with positive opioid withdrawal assessment. (Opioid withdrawal assessment will be repeated in 24 hours.)
• Any individual who has failed the naltrexone challenge test as evidenced by a change in COWS score of 2 or more
• Moderate to severe renal impairment

2 Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021897s015lbl.pdf
• History of thrombocytopenia or coagulation disorders

Assessment and Screening
• Individual confirmation of absence of opioid use for 7-10 days
• Negative urine drug screen for opioids
• Opioid withdrawal assessment as follows:
  o Naltrexone 25mg oral x1 (1/2 of a 50mg tablet)— with observation for
    60 minutes for signs and symptoms of opioid withdrawal.
  ▪ Prior to and following the 60-minute observation period:
    • Pharmacist will complete the Clinical Opiate Withdrawal
      Scale (COWS) {Appendix 1}

• Negative urine pregnancy test in females of child-bearing potential

If all inclusion and assessment criteria are met, pharmacists will administer long acting injectable naltrexone (Vivitrol®) 380 mg IM according to the manufacturer’s product information. Individuals receiving therapy will be monitored for adverse reactions for a period of 15 minutes. In the unlikely event of a serious or life-threatening allergic reaction, pharmacists will implement the attached anaphylaxis protocol {Appendix 2).

PROCEDURES FOR MONITORING AND CONTINUATION OF THERAPIES
Subsequent naltrexone will be dispensed and administered every 28 days (+/- 2 days) only in individuals who confirm absence of opioid use for 7-10 days and provide a negative urine drug screen for opioids. Individuals outside of 30 days since last injection will also require an opioid withdrawal assessment. Females of child-bearing potential must also have a negative urine pregnancy test.

Follow up monitoring and evaluation shall occur at a minimum at every 28 days (+/- 2 days) with each injection to determine effectiveness, adverse effects and individual progress with therapy, including participation in psychosocial treatment. If follow-up monitoring and evaluation indicates therapy continuation is warranted, naltrexone will be dispensed and administered every 28 days (+/- 2 days). Treatment periods longer than 12 months of continuous therapy are not authorized under this protocol without explicit approval from the authorizing prescriber.

Should follow-up evaluation and monitoring indicate continued therapy with extended-release injectable naltrexone is warranted, all procedures as outlined for initiation of therapies, including education, documentation and notification, will be followed.

EDUCATION REQUIREMENTS
Individuals receiving extended-release injectable naltrexone under the protocol will receive education regarding:
  1) Benefits, including the mechanism of action of naltrexone
  2) Alternatives to naltrexone
  3) Requirement of opioid free period for at least 7-10 days to avoid precipitation
of severe opioid withdrawal
4) Risk of opioid overdose at the end of duration of effect time period, if a dose is missed or treatment is discontinued, and in attempt to overcome blockade
5) Warnings and adverse effects possible with use of naltrexone
6) Expectation to carry and/or wear documentation of naltrexone treatment
7) Benefits of treatment shown only when used as part of a program that includes counseling and support
8) Use of rescue naloxone for emergency treatment of opiate overdose

*naloxone rescue medication will be provided under pharmacist naloxone protocol if individual does not have naloxone available.

A written medication guide (Appendix 3) will be provided to each individual at initiation of therapy.

DOCUMENTATION
Pharmacists shall document via prescription record each individual who receives naltrexone under this protocol, including:

(a) Documentation as required in 201 KAR 2:170 for the dispensing of prescription medication
(b) Documentation that the individual receiving naltrexone was provided with the required education pursuant to this protocol
(c) Documentation of informed consent to receive treatment
(d) Documentation of the history and assessment, of the care plan implemented and follow-up evaluation and monitoring, including individual confirmation of continued opioid free period and negative urine drug screen; and if applicable, negative urine pregnancy test and/or results of oral naltrexone challenge, including COWS assessment
(e) Documentation of medication lot and expiration; location of injection; and initials or NPI of administering pharmacist

NOTIFICATION
Pharmacist(s) shall provide notification of the medications dispensed and administered under the protocol to the primary care provider within two (2) business days. Any individual affirmatively stating that he/she does not have a primary care provider will be referred for a medical evaluation prior to initiating therapies under this protocol.

Pharmacist(s) shall provide notification if medication is ceased by the individual, or if administration is not warranted under conditions of the protocol, to the primary care provider within two (2) business days.

[If directed by the authorizing prescriber] the pharmacist shall provide written notification via fax or other secure electronic means to the authorizing prescriber of persons receiving naltrexone therapy under this protocol within 7 days of initiating dispensing.
TERMS
This protocol is effective as of the date all parties execute the document. It shall remain in effect for a period of one year and shall automatically renew for successive one year periods unless otherwise terminated by any party, with or without cause. Any termination without cause shall require prior notice to all parties of no less than sixty days.

SIGNATURES

Prescriber Name                           Date
Prescriber Signature

Pharmacist Name                           Date
Pharmacist Signature
APPENDIX 1
Clinical Opiate Withdrawal Scale

For each item, circle the number that best describes the patient’s signs or symptom. Rate on just the apparent relationship to opiate withdrawal. For example, if heart rate is increased because the patient was jogging just prior to assessment, the increase pulse rate would not add to the score.

<table>
<thead>
<tr>
<th>Patient’s Name:_____________________</th>
<th>Date and Time <em><strong><strong>/<strong><strong>/</strong></strong>:</strong></strong></em>__</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reason for this assessment:__________</td>
<td>----------------------------------------</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resting Pulse Rate: beats/minute</th>
<th>GI Upset: over last 1/2 hour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measured after patient is sitting or lying for one minute</td>
<td>0 no GI symptoms</td>
</tr>
<tr>
<td>0 pulse rate 80 or below</td>
<td>1 stomach cramps</td>
</tr>
<tr>
<td>1 pulse rate 81-100</td>
<td>2 nausea or loose stool</td>
</tr>
<tr>
<td>2 pulse rate 101-120</td>
<td>3 vomiting or diarrhea</td>
</tr>
<tr>
<td>4 pulse rate greater than 120</td>
<td>5 multiple episodes of diarrhea or vomiting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sweating: over past 1/2 hour not accounted for by room temperature or patient activity.</th>
<th>Tremor: observation of outstretched hands</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 no report of chills or flushing</td>
<td>0 no tremor</td>
</tr>
<tr>
<td>1 subjective report of chills or flushing</td>
<td>1 tremor can be felt, but not observed</td>
</tr>
<tr>
<td>2 flushed or observable moistness on face</td>
<td>2 slight tremor observable</td>
</tr>
<tr>
<td>3 beads of sweat on brow or face</td>
<td>4 gross tremor or muscle twitching</td>
</tr>
<tr>
<td>4 sweat streaming off face</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Restlessness Observation during assessment</th>
<th>Yawning Observation during assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 able to sit still</td>
<td>0 no yawning</td>
</tr>
<tr>
<td>1 reports difficulty sitting still, but is able to do so</td>
<td>1 yawning once or twice during assessment</td>
</tr>
<tr>
<td>3 frequent shifting or extraneous movements of legs/arms</td>
<td>2 yawning three or more times during assessment</td>
</tr>
<tr>
<td>5 unable to sit still for more than a few seconds</td>
<td>4 yawning several times/minute</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pupil size</th>
<th>Anxiety or Irritability</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 pupils pinned or normal size for room light</td>
<td>0 none</td>
</tr>
<tr>
<td>1 pupils possibly larger than normal for room light</td>
<td>1 patient reports increasing irritability or anxiousness</td>
</tr>
<tr>
<td>2 pupils moderately dilated</td>
<td>2 patient obviously irritable or anxious</td>
</tr>
<tr>
<td>5 pupils so dilated that only the rim of the iris is visible</td>
<td>4 patient so irritable or anxious that participation in the assessment is difficult</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bone or Joint aches If patient was having pain previously, only the additional component attributed to opiates withdrawal is scored</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 not present</td>
</tr>
<tr>
<td>1 mild diffuse discomfort</td>
</tr>
<tr>
<td>2 patient reports severe diffuse aching of joints/muscles</td>
</tr>
<tr>
<td>4 patient is rubbing joints or muscles and is unable to sit still because of discomfort</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Runny nose or tearing Not accounted for by cold symptoms or allergies</th>
<th>Total Score ________</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 not present</td>
<td>The total score is the sum of all 11 items</td>
</tr>
<tr>
<td>1 nasal stuffiness or unusually moist eyes</td>
<td></td>
</tr>
<tr>
<td>2 nose running or tearing</td>
<td></td>
</tr>
<tr>
<td>4 nose constantly running or tears streaming down cheeks</td>
<td></td>
</tr>
</tbody>
</table>

Score: 5-12 = mild; 13-24 = moderate; 25-36 = moderately severe; more than 36 = severe withdrawal

This version may be copied and used clinically.
Appendix 2
Addendum for Management of Adverse Reactions to Naltrexone

All medications have the potential to cause an adverse reaction. In order to minimize adverse reactions, individuals must be carefully screened for precautions and contraindications before the medication is administered. Even with careful screening, reactions may occur. These reactions can vary from trivial and inconvenient (e.g. soreness, itching) to severe and life threatening (e.g. anaphylaxis). If reactions occur, the pharmacists must be prepared with procedures for their management.

Anaphylactic Reactions

Signs and symptoms of anaphylactic reaction include:
- the sudden or gradual onset of generalized itching, erythema (redness), or urticaria (hives);
- angioedema (swelling of the lips, face, or throat);
- bronchospasm (wheezing);
- shortness of breath;
- shock;
- abdominal cramping; or
- cardiovascular collapse.

The following procedures should be used to manage anaphylactic reactions following administration:

1. If itching and swelling are confined to the injection site, observe closely for at least 30 minutes, watching for the development of generalized symptoms.
2. If symptoms are generalized, activate the emergency medical system (e.g., call 911) immediately.
   a. Administer diphenhydramine for hives or generalized itching, either orally or by intramuscular injection.
      - The standard dose is 1-2 mg/kg every 4-6 hours, or 50 to 100 mg maximum single dose for adults. Do not attempt to give oral medications to an individual who is not fully alert and able to swallow safely.
3. Place individual in a recumbent position and elevate legs.
4. The first-line therapy in anaphylaxis is epinephrine. There are no contraindications to epinephrine in the setting of anaphylaxis.
   a. Administer aqueous epinephrine 1:1000 dilution intramuscularly, 0.01mL/kg/dose (adult dose ranges from 0.3mL to 0.5mL, with a maximum single dose of 0.5mL), as indicated:

<table>
<thead>
<tr>
<th>Weight (lbs)</th>
<th>Weight (kg)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>45-88 lb</td>
<td>21-40 kg</td>
<td>0.3mg (or mL)</td>
</tr>
<tr>
<td>89-110 lbs</td>
<td>41-50 kg</td>
<td>0.45mg (or mL)</td>
</tr>
<tr>
<td>&gt;110 lbs</td>
<td>&gt;51 kg</td>
<td>0.5mg (or mL)</td>
</tr>
</tbody>
</table>
Prefilled devices (i.e., EpiPen or similar autoinjector):
Weight > 66 lbs or 30 kg – EpiPen 0.30mg

The site of injection can be gently massaged to facilitate absorption.

(b) If EMS has not arrived and symptoms are still present, the dose of epinephrine may be repeated every 5 to 15 minutes for up to 3 doses, depending on the individual’s response.

For all adverse reactions the following procedures should be used:
• Monitor the individual closely and check vital signs (blood pressure, pulse, and respirations) every 2 to 5 minutes.
• Stay with individual until EMS arrives.
• If necessary, perform cardiopulmonary resuscitation (CPR) and maintain airway.
• Keep individual in supine position unless he or she is having breathing difficulty. If breathing is difficult, individual’s head may be elevated, provided blood pressure is adequate to prevent loss of consciousness. If blood pressure is low, elevate legs.
• Notify the authorizing prescriber and, if applicable the primary care provider as soon as possible.
Appendix 3: Vivitrol Medication Guide

MEDICATION GUIDE

VIVITROL (oxycodone for extended-release injectable suspension)

Read this Medication Guide before you start receiving VIVITROL injections and each time you receive an injection. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

What is the most important information I should know about VIVITROL?
VIVITROL can cause serious side effects, including:

1. Risk of opioid overdose. You can accidentally overdose in two ways:
  - VIVITROL blocks the effects of opioids, such as heroin or opioid pain medicines. Be mindful of large amounts of opioids, including opioid-containing medicines, such as heroin or prescription pain pills, so you do not overdose.
  - After you receive a dose of VIVITROL, blocking effect slowly decreases and completely gone over one or two days. If you have used opioid street drugs or opioid-containing medicines in the past, using opioids in amounts that you used before treatment with VIVITROL can lead to overdose and death. You may also be more sensitive to the effects of lower amounts of opioids.

It is important that you will tell your family and the people closest to you of this increased sensitivity to opioids and the risk of overdose.

Tell your healthcare provider about any reaction at an injection site that concerns you, gets worse over time, or does not get better by two weeks after the injection.

2. Severe reactions at the site of the injection (injection site reactions). Some people on VIVITROL have had severe injection site reactions, including tissue death (necrosis). Some of these injection site reactions have required surgery. Call your healthcare provider right away if you notice any of the following at any of your injection sites:
  - intense pain
  - the area feels hard
  - large area of swelling
  - bumps

Tell your healthcare provider about any reaction at an injection site that concerns you, gets worse over time, or does not get better by two weeks after the injection.

3. Sudden opioid withdrawal. Anyone who receives VIVITROL injection must not use any type of opioid (opioids) that can cause withdrawal including street drugs, prescription pain medicines, cough, cold, or allergy medicine that contain opioids, and opioid dependence treatments. Symptoms of opioid withdrawal for at least 7 to 14 days after stopping VIVITROL may cause you to suddenly have symptoms of opioid withdrawal when you get the VIVITROL injection. Sudden opioid withdrawal can be severe, and you may need to go to the hospital.

You must be opioid-free before receiving VIVITROL. Your healthcare provider decides that you need to get through this first. Instead, your doctor may decide to give you a VIVITROL injection that is an opioid-free medication that can treat you for sudden opioid withdrawal.

4. Visual damage or retinopathy. VIVITROL can cause vision damage or retinopathy.

Tell your healthcare provider if you have any of the following symptoms of vision problems during treatment with VIVITROL:
  - floaters
  - blurring of vision
  - difficulty seeing at night

Your healthcare provider may need to stop treating you with VIVITROL if you get signs or symptoms of a serious eye problem.

What is VIVITROL?
VIVITROL is a prescription medicine used to:
- treat opioid dependence. You should stop taking before starting VIVITROL.
- prevent relapse of opioid dependence, after opioid identification.

Your doctor can tell you if you have taken opioids or opioid-containing medicines, you may need to take it before you start taking VIVITROL. See “What is the most important information I should know about VIVITROL?”

Tell your doctor and healthcare provider about any reactions to VIVITROL or other opioid or drug recovery programs such as counseling. VIVITROL may not work for everyone.

It is unknown if VIVITROL is safe and effective in children.

Who should not receive VIVITROL?
Do not receive VIVITROL if you:
- are using or have a physical dependence of opioid-containing medicines or opioid street drugs
- have a history of seizures or use of medicines that affect the central nervous system
- have gone through detoxification
- have a substance abuse disorder
- you have any of these symptoms before taking VIVITROL:
  - severe liver or kidney disease

Tell your healthcare provider if you have any of these symptoms before taking VIVITROL.

Symptoms of opioid withdrawal may include:
- anxiety, sleeplessness, restlessness, tremor, sweating, muscle stiffness, yawning, tissue, diarrhea, nausea, vomiting, cramps, or bowel urgency. See “What is the most important information I should know about VIVITROL?”

Tell your healthcare provider if you have any of these symptoms before taking VIVITROL.
What should I tell my healthcare provider before receiving VINTEROL? Before you receive VINTEROL, tell your healthcare provider:

- have liver problems
- use or have used oral anticoagulants
- have bleeding problems
- have kidney problems
- have any other medical conditions
- are pregnant or plan to become pregnant. It is not known if VINTEROL will harm your unborn baby.
- are breastfeeding. It is not known if VINTEROL passes into your milk, and it could harm your baby. VAHSLREX, the active ingredient in VINTEROL, is the same active ingredient in aminosalicylic acid that can harm your baby. VINTEROL does not contain aminosalicylic acid. Talk to your doctor about whether you will breastfeed or take VINTEROL. You should not breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you take any opioid-containing medicines for pain, cough or colds, or diarrhea, see "What is the most important information I should know about VINTEROL?"

If you are being treated for alcohol dependence but also use or are addicted to opioid-containing medicines or opioid street drugs, it is important that you tell your healthcare provider before starting VINTEROL to avoid using opioids or opioid substances when you start VINTEROL treatment.

Since the medicines you take, keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How will I receive VINTEROL?

- VINTEROL is injected by a healthcare provider, about 1 time each month
- VINTEROL is given as an injection into a muscle in your buttocks using a special needle. You should not receive VINTEROL by a needle that came with another medicine. Ask your healthcare provider about your injection. Schedule your appointment as soon as possible. See "What is the most important information I should know about VINTEROL?"
- If you miss an appointment for your VINTEROL injection, schedule another appointment as soon as possible. See "What is the most important information I should know about VINTEROL?"
- If you are on a medical treatment, be sure to tell the nursing healthcare provider that you are receiving VINTEROL injections and exercise when you get your last dose. This is important because some VINTEROL, and other injections of opioid-containing medicines that might be prescribed for you for pain, cough, or colds, or diarrhea.
- Carry written information with you at all times to alert healthcare providers that you are receiving VINTEROL, so that they can treat you properly in an emergency. Ask your healthcare provider how you can get a wallet card to carry with you.

What should I avoid while receiving VINTEROL?

Do not drive, operate machinery, or do other dangerous activities until you know how VINTEROL affects you. VINTEROL may make you feel dizzy and sleepy. See "What are the possible side effects of VINTEROL?"

What are the possible side effects of VINTEROL?

- See "What is the most important information I should know about VINTEROL?"
- "Depressed mood. Sometimes this leads to suicide, or suicidal thoughts and suicidal behavior. Tell your family members and people closest to you that you are taking VINTEROL. You, a family member, or the people closest to you should call your healthcare provider right away if you become depressed or have any of the following symptoms of depression, especially if they are new, worse, or worry you.
- You feel sad or have crying spells.
- You are not interested in eating your food or doing things you used to enjoy.
- You are sleeping too much or too little than usual.
- You feel tired or have trouble sleeping.
- You feel tired or are very sluggish.
- You are more irritable, angry, or aggressive than usual.
- You are more or less hungry than usual or notice a big change in your body weight.
- You have trouble paying attention.
- You feel tired or have trouble sleeping.
- You have thoughts about hurting yourself or ending your life.
- Symptoms of withdrawal. People taking VINTEROL for a long time may get symptoms of withdrawal if their treatment is stopped. If this happens to you, you may need to be treated in the hospital. Tell your healthcare provider right away if you have any of these symptoms during treatment with VINTEROL:
- appetites.
- sweating.
- staying up all night or sleeping too much.
- troubled breathing or sweating
- dizziness
- feeling dizzy or faint.

Common side effects of VINTEROL may include:
- diarrhea
- nausea
- vomiting
- abdominal pain
- constipation
- headache
- chills
- nausea
- headache
- constipation
- abdominal pain
- vomiting
- dizziness
- feeling dizzy or faint.

These are not all the side effects of VINTEROL. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What are the ingredients in VINTEROL?
- Active ingredient: methadone hydrochloride
- Inactive ingredients: polyethylene glycol 400, sodium metabisulfite, sodium chloride, and water for injection

This medication guide has been approved by the U.S. Food and Drug Administration.

Manufactured and marketed by:
- Allergan, Inc.

352 White Street
William, MA 02694-1369

Allergan, Inc. and VINTEROL are registered trademarks of Allergan, Inc.